Home/Filings/4/0001235802-20-000136
4//SEC Filing

Eggenberg Michael 4

Accession 0001235802-20-000136

CIK 0001453593other

Filed

Nov 18, 7:00 PM ET

Accepted

Nov 19, 5:33 PM ET

Size

30.2 KB

Accession

0001235802-20-000136

Insider Transaction Report

Form 4
Period: 2020-11-17
Eggenberg Michael
Director10% Owner
Transactions
  • Exercise of In-Money

    Warrant (right to buy)

    2020-11-17868,0160 total(indirect: See Footnotes)
    Exercise: $0.01From: 2020-11-06Exp: 2030-05-06Common Stock (868,016 underlying)
  • Exercise of In-Money

    Common Stock

    2020-11-17$0.01/sh+434,008$4,34016,168,704 total(indirect: See Footnotes)
  • Exercise of In-Money

    Warrant (right to buy)

    2020-11-17765,9920 total(indirect: See Footnotes)
    Exercise: $0.01From: 2018-09-17Exp: 2028-08-01Common Stock (765,992 underlying)
  • Exercise of In-Money

    Common Stock

    2020-11-17$0.01/sh+765,992$7,66053,468,376 total(indirect: See Footnotes)
  • Exercise of In-Money

    Common Stock

    2020-11-17$0.01/sh+1,531,984$15,32055,766,352 total(indirect: See Footnotes)
  • Exercise of In-Money

    Warrant (right to buy)

    2020-11-17765,9920 total(indirect: See Footnotes)
    Exercise: $0.01From: 2019-04-11Exp: 2029-04-01Common Stock (765,992 underlying)
  • Exercise of In-Money

    Warrant (right to buy)

    2020-11-17434,0080 total(indirect: See Footnotes)
    Exercise: $0.01From: 2019-04-11Exp: 2029-04-01Common Stock (434,008 underlying)
  • Exercise of In-Money

    Warrant (right to buy)

    2020-11-171,531,9840 total(indirect: See Footnotes)
    Exercise: $0.01From: 2020-11-06Exp: 2030-05-06Common Stock (1,531,984 underlying)
  • Exercise of In-Money

    Common Stock

    2020-11-17$0.01/sh+765,992$7,66054,234,368 total(indirect: See Footnotes)
  • Exercise of In-Money

    Common Stock

    2020-11-17$0.01/sh+434,008$4,34015,734,696 total(indirect: See Footnotes)
  • Exercise of In-Money

    Common Stock

    2020-11-17$0.01/sh+868,016$8,68017,036,720 total(indirect: See Footnotes)
  • Exercise of In-Money

    Warrant (right to buy)

    2020-11-17434,0080 total(indirect: See Footnotes)
    Exercise: $0.01From: 2018-09-17Exp: 2028-08-01Common Stock (434,008 underlying)
Holdings
  • Common Stock

    70,423
Footnotes (4)
  • [F1]These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.
  • [F2]Each of ROS Acquisition, OrbiMed Royalty Opportunities II, LP ("ORO II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.
  • [F3]These securities are held of record by ORO II. OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II.
  • [F4]These shares are to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the Reporting Person remaining a director of the Company through the vesting date.

Issuer

Xtant Medical Holdings, Inc.

CIK 0001453593

Entity typeother

Related Parties

1
  • filerCIK 0001732521

Filing Metadata

Form type
4
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 5:33 PM ET
Size
30.2 KB